Associated tags: NK, CELU, Biology, Cancer, Instituto de Biologia Molecular e Celular, Pharmaceutical industry, Patient, CAR
Locations: FLORHAM PARK, NEW JERSEY, US, CA, CORNEA, KOREA, PARK, UNITED STATES
These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.
Key Points:
- These data, which highlight the platform’s robust anti-tumor activity against gastric cancer will be presented on April 9th, 2024.
- Celularity is developing a platform to combine a broad portfolio of cell therapies with various approved antibodies to address multiple cancers and other conditions.
- Celularity’s preclinical asset, PT-CD16VS, is initially being developed in combination with trastuzumab, a cancer drug, for treating HER2-positive cancers.
- “These data demonstrate the promise and potential of combining Celularity’s cell therapy assets with currently available therapies to address difficult-to-treat cancers,” said Dr. Robert Hariri, Celularity’s CEO and Founder.
Retrieved on:
Friday, February 23, 2024
Accordingly, the public and private warrants that are currently traded under the ticker symbol “CELUW” will be proportionally adjusted such that every 10 shares of Common Stock that may be purchased pursuant to the warrants immediately prior to the reverse stock split now represent one share of Common Stock that may be purchased immediately following the reverse stock split.
Key Points:
- Accordingly, the public and private warrants that are currently traded under the ticker symbol “CELUW” will be proportionally adjusted such that every 10 shares of Common Stock that may be purchased pursuant to the warrants immediately prior to the reverse stock split now represent one share of Common Stock that may be purchased immediately following the reverse stock split.
- Correspondingly, the exercise price per share of Class A common stock attributable to such warrants immediately prior to the reverse stock split has been proportionately increased, such that the exercise price immediately following the reverse stock split is $115.
- Continental Stock Transfer and Trust, Celularity’s transfer agent, will act as the exchange agent for the reverse stock split.
- In connection with the reverse stock split, the CUSIP number for Celularity’s post-split Class A common stock will change to 151190 204.
Retrieved on:
Wednesday, February 14, 2024
Engineering,
Regeneration,
Regenerative medicine,
Inflammation,
North Carolina State University,
Neovascularization,
Infection,
South Korea,
WBC,
Wilson College,
Tissue engineering,
KSBM,
Decellularization,
Congress,
CELU,
Trauma,
Tissue,
Development,
Culture of Korea,
LSC,
Wound healing FLORHAM PARK, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its abstract “Tri-layer decellularized, dehydrated human amniotic membrane supports proliferation and stemness of limbal stem cells derived from induced pluripotent stem cells” has been accepted as a poster presentation at WBC 2024, the 12th World Biomaterials Congress which will be held on 26-31 May 2024 in Daegu, Republic of Korea, and hosted by the Korean Society for Biomaterials (KSBM). The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”
Key Points:
- The theme of WBC 2024 is “Convergence in Biomaterials: a vision for the future of healthcare.”
The study described in the poster presentation investigated Celularity’s tri-layer decellularized, dehydrated human amniotic membrane technology product as a carrier of induced pluripotent stem cell derived-limbal stem cells (iPSC-LSC) which were investigated for the treatment of limbal stem cell deficiency (LSCD).
- Limbal Stem Cell (LSC) transplant is a recognized method to restore the ocular surface in advanced stem cell deficient corneas.
- Its Tissue Engineering Lab Team is particularly interested in corneal tissue engineering, focusing primarily on ocular surface regeneration.
- The off-the-shelf availability of existing commercial tri-layer decellularized, dehydrated human amniotic membrane products, in combination with iPSC-LSCs, may improve patient access to LSCD treatment and the therapeutic management of LSCD.
Retrieved on:
Thursday, February 1, 2024
Traction,
Growth,
Umbilical cord,
Extracellular matrix,
Extremities,
Regenerative medicine,
Chronic pain,
Combination,
Collagen,
Pelvis,
CELU,
Cytokine,
Knee,
Environment,
Exosome,
FDA,
Disorder,
Osteoarthritis,
Device,
Food,
Decellularization,
Dentistry,
Protein,
Disability,
Chemokine,
Sale,
Tissue,
GMP,
Burns,
Pharmaceutical industry FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline. As used here, “net sales” refers exclusively to revenue from the sale of advanced biomaterial products and biobanking services, respectively, and does not include any revenue from other sources such as license fees and royalties or revenue earned under research collaboration agreements.
Key Points:
- FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced expected net sales of its biomaterial products and biobanking businesses for the first quarter 2024 and the full year 2024, respectively, and reiterated its previously disclosed advanced biomaterial product commercial and development pipeline.
- “Our sales of advanced biomaterial products grew dramatically in the fourth quarter of 2023 as our newest Biovance 3L product gained traction.
- The Company expects in future to update expected full year 2024 net sales of its advanced biomaterial product and biobanking businesses.
- The Company’s advanced biomaterial product pipeline consists of four commercial-stage products and three development-stage product candidates.
Retrieved on:
Thursday, January 25, 2024
The other financing transaction is an agreement amending and restating the Company’s previously announced senior secured loan agreement with Resorts World Inc Pte Ltd. (“RWI”) for an additional loan of $15.0 million.
Key Points:
- The other financing transaction is an agreement amending and restating the Company’s previously announced senior secured loan agreement with Resorts World Inc Pte Ltd. (“RWI”) for an additional loan of $15.0 million.
- According to Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder, “These transactions are important in two fundamental ways.
- First, both Dragasac and RWI increased their existing financial stakes in Celularity, Dragasac through the $6 million private placement and RWI through the $15 million amended and restated senior secured loan.
- Second, the transactions together infused $21 million of fresh capital into Celularity, which we will apply to strengthen our balance sheet and for other purposes.
Retrieved on:
Thursday, January 18, 2024
NK,
Regenerative medicine,
Research,
Biology,
Biotechnology,
Science,
Regeneron Pharmaceuticals,
Letter,
Cancer,
Sale,
Longevity,
CELU,
Ageing,
Growth,
Pharmaceutical industry FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here .
Key Points:
- FLORHAM PARK, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here .
- Within the last few weeks, we announced net sales expectations for the fourth quarter 2023 and the full year 2023, respectively.
- As you have all witnessed, Celularity has struggled to keep Celularity operating through this period and our valuation has been severely impacted by market conditions.
- As you all know, I have personally continued to invest heavily in Celularity because my commitment is unwavering.
Retrieved on:
Thursday, January 4, 2024
FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications.
Key Points:
- FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft, Inc. (“BioCellgraft”) under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications.
- A copy of BioCellgraft’s announcement of the agreement can be accessed here: https://www.prweb.com/releases/biocellgraft-finalizes-commercialization-... .
- Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder of Celularity, said, “This commercialization agreement with BioCellgraft opens an important pathway for Celularity-manufactured, BioCellgraft-branded and marketed advanced biomaterial products into dental and oral healthcare applications in the United States that include periodontology, implant dentistry and oral surgery, all of which are large and growing markets.”
Retrieved on:
Wednesday, January 3, 2024
FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023.
Key Points:
- Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively.
- FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company), a biotechnology company developing allogeneic cell therapies and biomaterial products, today announced expected net sales of its advance biomaterial products and biobanking businesses for the fourth quarter 2023 and the full year 2023 and expected total revenue for the fourth quarter 2023 and the full year 2023.
- For the fourth quarter 2023, the Company expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million and the net sales percentage growth to be in the range of 176.1% to 193.0% compared to the fourth quarter 2022.
- The Company anticipates that it will announce actual net sales and actual total revenue for the fourth quarter of 2023 and the full year of 2023 later this year.
Retrieved on:
Friday, November 24, 2023
The Company intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period.
Key Points:
- The Company intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period.
- However, there can be no assurance that the Company will regain compliance within the compliance period, or maintain compliance with the other Nasdaq listing requirements.
- As previously disclosed, the Company is currently not in compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5450(a)(1) and has until March 11, 2024, to regain compliance.
- If the Company chooses to implement a reverse stock split, it must be completed no later than 10 business days prior to March 11, 2024 to timely regain compliance.
Retrieved on:
Wednesday, October 18, 2023
Islam,
Halal certification in Australia,
Certification,
Umbilical cord,
Placenta,
Trauma,
PTD,
Partnership,
Saudi Food and Drug Authority,
CELU,
Classification,
Kingdom,
SFDA,
Medical device,
Sharia,
Instituto de Biologia Molecular e Celular FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority (SFDA) as “Minimally Manipulated Biological Products” for importation license purposes in the Kingdom of Saudi Arabia. The SFDA independently reviewed and issued classifications for each of the following Celularity Halal Certified biomaterial products:
Key Points:
- FLORHAM PARK, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced that its Halal Certified biomaterial products have been classified by the Saudi Food and Drug Authority (SFDA) as “Minimally Manipulated Biological Products” for importation license purposes in the Kingdom of Saudi Arabia.
- The SFDA independently reviewed and issued classifications for each of the following Celularity Halal Certified biomaterial products:
Biovance®, a decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy.
- Biovance® is an intact, extracellular matrix structure that provides a natural scaffold to support the body’s wound-healing process.
- “The SFDA’s Minimally Manipulated Biological Product classification establishes a clear regulatory pathway for the importation of our Halal Certified biomaterial products into Saudi Arabia,” said Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder of Celularity.